The implementation of decentralised clinical trials amid the pandemic involves significant changes to conventional procedures.
GlobalData conducted a survey to identify the top changes that the companies feel will be necessary while transitioning to DCTs.
Biggest Changes Needed to Pivot to Decentralised Clinical Trials
According to the survey results, around 17% of the respondents feel that systems integrations and alignment will be required while switching to DCTs.
It is followed closely by process changes and alignment (16%) and training (16%).
Around 15% of the respondents opined that changes to regulatory/ operational risk assessments will be the biggest change needed to pivot decentralised trials, while another 13% highlighted adjustments in upfront planning and coordination for study execution.
The percentage of respondents who said that changes in study design will be required to transition to DCT stands at 13%.
On the other hand, only 9% stated that changes in the organisational structure will be required indicating that the organisations feel that the distribution of work will be easier while switching to decentralised trials.
The analysis is based on responses received for the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.